Patenteral formulation of flavopiridol (NSC-649890)

Rose Marie Dannenfelser, Yosyong Surakitbanharn, S. Esmail Tabibi, Samuel H. Yalkowsky

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6'-chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither cosolvency, complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30% hydroxypropyl β-cydodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen 's phosphate buffer pH 7.4.

Original languageEnglish (US)
Pages (from-to)356-359
Number of pages4
JournalPDA Journal of Pharmaceutical Science and Technology
Volume50
Issue number6
StatePublished - Nov 1 1996

    Fingerprint

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Dannenfelser, R. M., Surakitbanharn, Y., Tabibi, S. E., & Yalkowsky, S. H. (1996). Patenteral formulation of flavopiridol (NSC-649890). PDA Journal of Pharmaceutical Science and Technology, 50(6), 356-359.